Thirty Madison Medical Leadership and Credentials: An Independent Review

What Is Thirty Madison and How Does Its Medical Model Work?

Thirty Madison is a New York-based direct-to-consumer telehealth holding company. It does not operate a single generalist platform. Instead it runs separate condition-focused brands, each with its own clinical team, formulary, and patient-facing interface. Keeps targets androgenetic alopecia in men and women. Cove specializes in migraine prevention and acute treatment. Facet addresses acne, hyperpigmentation, and anti-aging skin concerns. Sadie provides hormonal and non-hormonal contraception.

The Portfolio Structure

Each brand has a dedicated medical director (or equivalent licensed physician leader) responsible for clinical protocols, formulary decisions, and prescriber oversight. Thirty Madison has not published a unified medical advisory board page with individual board-certification details or state licensure lists as of early 2025. That omission makes independent credential verification harder than it should be for a company serving hundreds of thousands of patients.

How Prescriptions Are Issued

Patients complete an online intake questionnaire. A licensed physician or nurse practitioner reviews responses asynchronously or, for certain medications, synchronously via video. Prescriptions go to a partner pharmacy. The FDA requires that any prescriber issuing a prescription for finasteride include the drug's Medication Guide, which discloses risks of sexual dysfunction, depression, and, in rare cases, suicidal ideation [1]. Whether Keeps consistently delivers that guide with every shipment has been a documented consumer complaint on the Better Business Bureau platform.

Are the Medications Thirty Madison Prescribes FDA-Approved?

Yes. Every medication dispensed across Thirty Madison's brands holds FDA approval for at least one indication the company treats. This is the most basic safety threshold for any telehealth company, and Thirty Madison meets it.

Keeps Formulary

Keeps prescribes finasteride 1 mg (FDA-approved for male androgenetic alopecia since 1997) and topical or oral minoxidil. The FDA approved a 2% and 5% topical minoxidil solution for androgenetic alopecia decades ago [2]. Oral minoxidil at low doses (0.25 mg to 5 mg) is increasingly used off-label for hair loss; the FDA has not approved an oral formulation specifically for alopecia, only for severe hypertension [3]. Keeps should disclose this off-label status explicitly to patients.

Cove Formulary

Cove prescribes acute migraine medications including sumatriptan, rizatriptan, and ubrogepant, as well as preventive agents such as topiramate and propranolol. The American Headache Society's 2021 evidence-based guideline designates triptans as first-line acute therapy for moderate-to-severe migraine [4]. Topiramate carries an FDA Medication Guide requirement for suicidal behavior and ideation, which Cove's prescribers are obligated to address [5].

Facet and Sadie Formularies

Facet prescribes tretinoin (FDA-approved for acne since 1971) and other topical agents. Tretinoin is teratogenic; FDA labeling requires pregnancy counseling at initiation [6]. Sadie prescribes combined oral contraceptives and progestin-only pills. The FDA's prescribing information for combined oral contraceptives requires cardiovascular risk screening, particularly for women who smoke and are older than 35 [7].

Who Are the Physicians Behind Thirty Madison's Brands?

This is the most significant credentialing gap in Thirty Madison's public-facing presence. Legitimate telehealth companies typically publish named medical directors with their state medical license numbers, board certifications, and professional affiliations.

What Thirty Madison Has Disclosed

Thirty Madison has named a Chief Medical Officer in press materials at various points, but the company's website as of early 2025 does not display a comprehensive, up-to-date medical team page with verifiable credentials for every brand. Individual prescribers are not listed by name and license number in the way that, for example, a brick-and-mortar multi-specialty group practice would display on a state board website.

How to Verify Independently

Patients can verify any prescriber through their state medical board. The Federation of State Medical Boards maintains a consolidated physician lookup tool at fsmb.org. For New York-licensed physicians, the New York State Department of Health Office of Professional Medical Conduct maintains public disciplinary records. The FDA's MedWatch reporting system accepts adverse event reports from patients who believe a telehealth prescriber caused harm [8].

Board Certification Standards

The American Board of Medical Specialties (ABMS) recognizes 24 member boards covering specialties relevant to Thirty Madison's brands: dermatology (American Board of Dermatology), neurology (American Board of Psychiatry and Neurology, which also certifies headache medicine through subspecialty examination), and obstetrics/gynecology (American Board of Obstetrics and Gynecology) [9]. A company prescribing in these specialty areas should, at minimum, have board-certified physicians supervising clinical protocols. Thirty Madison has not publicly confirmed which supervising physicians hold ABMS certification in the relevant subspecialties.

Is Thirty Madison Legit? Regulatory and Accreditation Status

"Legit" in telehealth means at least three things: the company operates lawfully, the medications are genuine, and the prescribing meets the standard of care. Thirty Madison appears to satisfy the first two criteria. The third is harder to assess from outside the clinical encounter.

State Licensing and Corporate Practice of Medicine

Telehealth companies must comply with each state's corporate practice of medicine doctrine. Most states prohibit lay corporations from directly employing physicians; instead, a physician-owned professional corporation contracts with the management company. Thirty Madison uses this PC/MSO (professional corporation/management services organization) model, standard in the industry. Whether its physician PCs are structured correctly in every state it serves is a legal question that requires state-by-state analysis the company has not made publicly available.

BBB Profile and Consumer Complaints

The Better Business Bureau profile for Thirty Madison (and its sub-brands) reflects mixed consumer sentiment. Common complaint themes include difficulty canceling subscriptions, unexpected charges, and delays in prescription processing. These are operational complaints, not clinical safety reports, but they are material to overall trustworthiness. The BBB complaint pattern for subscription-based telehealth is not unique to Thirty Madison. The FTC has taken action against other subscription telehealth companies for deceptive billing practices, a regulatory risk the sector broadly faces [10].

LegitScript Certification

LegitScript is a third-party verification service that certifies online pharmacies and telehealth platforms for compliance with applicable laws. As of early 2025, Thirty Madison's dispensing pharmacy partners' LegitScript status is not prominently disclosed on the company's consumer-facing websites. Patients can query the LegitScript lookup tool directly using the dispensing pharmacy name found on their prescription label.

FDA Adverse Event Data

The FDA's FAERS (FDA Adverse Event Reporting System) database contains voluntary reports from patients and providers. Searching FAERS for finasteride adverse events reveals thousands of reports of sexual dysfunction and mood disorders, consistent with the drug's known pharmacology [11]. These are not Thirty Madison-specific, but they are relevant because Keeps is finasteride's largest D2C distribution channel in the United States by volume. Patients who experience adverse events should report them via FDA MedWatch [8].

Clinical Evidence for Thirty Madison's Core Treatments

A company's legitimacy partly rests on whether it prescribes treatments with genuine clinical evidence. Across its brands, Thirty Madison's formulary holds up reasonably well to scrutiny.

Hair Loss: Finasteride and Minoxidil Evidence

The 1-year key trial for finasteride 1 mg (N=1,553 men with mild-to-moderate androgenetic alopecia) demonstrated statistically significant improvements in hair count and investigator assessment versus placebo (P<0.001) [12]. A Cochrane review of minoxidil for androgenetic alopecia (2012, updated evidence pooled across 27 trials) found that topical minoxidil 5% produced significantly more responders than 2% formulation and placebo [13]. The evidence for oral minoxidil at doses used by Keeps (typically 0.625 mg to 2.5 mg) is more limited; a 2021 systematic review in the Journal of the American Academy of Dermatology included 17 studies but noted most were retrospective and uncontrolled [14].

Migraine: Cove's Triptan and Preventive Evidence

The 2012 American Headache Society evidence classification gave triptans a Level A recommendation for acute migraine [4]. Topiramate's efficacy for migraine prevention was established in two multicenter randomized controlled trials (N=469 and N=487 respectively) published in the Archives of Neurology showing 50% responder rates of approximately 47% versus 23% placebo at 100 mg/day [15]. These are the trials underpinning Cove's preventive prescribing.

Contraception and Skin: Sadie and Facet

Combined oral contraceptives reduce the risk of unintended pregnancy to roughly 0.3% per year with perfect use, per the CDC's 2024 Medical Eligibility Criteria for Contraceptive Use [16]. Tretinoin's efficacy for acne is well established across decades of controlled trials; a 2016 meta-analysis in the British Journal of Dermatology confirmed significant reductions in inflammatory lesion counts versus vehicle [17].

Original HRX Framework: Five Questions to Ask Any Telehealth Brand Before You Fill a Prescription

The following five-question checklist was developed by the HealthRX medical team as a practical decision tool for patients evaluating any D2C telehealth company, including Thirty Madison. No single question is sufficient; all five matter.

1. Are the prescribing physicians individually identifiable and verifiable? The company should list each prescriber's name, state license number, and specialty. You should be able to look them up on your state medical board's public portal within two minutes.

2. Does the formulary consist entirely of FDA-approved medications, or does it include off-label use that is explicitly disclosed? Off-label prescribing is legal and sometimes appropriate, but the patient must be told. If a company prescribes oral minoxidil for hair loss without disclosing off-label status, that is an informed-consent failure.

3. Is there a synchronous clinical encounter available for medications that carry FDA Medication Guide requirements? Finasteride, topiramate, and combined oral contraceptives all carry mandatory FDA labeling that requires meaningful patient counseling. An asynchronous questionnaire does not reliably substitute for a conversation about suicidal ideation risk or thromboembolic risk.

4. What is the cancellation and refill policy, and is it clearly disclosed before purchase? Billing complaints dominate BBB filings for subscription telehealth. Read the cancellation terms before subscribing.

5. What happens if you have an adverse event? The company should provide a clear pathway to reach a licensed clinician within 24 hours for urgent adverse reactions, not just a chatbot or email queue.

Thirty Madison Complaints: What Patients Report

Aggregated consumer complaint data from the BBB, Trustpilot, and Reddit communities (r/Keeps, r/tressless) reveals several recurrent themes worth examining independently.

Subscription and Billing Disputes

The most common complaint category is subscription cancellation difficulty and unexpected charges. This pattern is not unique to Thirty Madison; it is endemic to subscription-model telehealth. The FTC's 2023 "Click-to-Cancel" rulemaking targets exactly these practices across the e-commerce sector [10].

Asynchronous Care Quality Concerns

A subset of patients reports that prescription renewals occurred without any clinician review of side effects or updated medical history. For finasteride, this is a clinical safety concern. The FDA's guidance on telehealth prescribing does not set a mandatory review interval, but the American Academy of Dermatology's hair loss management guidelines suggest annual reassessment at minimum [18].

Shipping and Pharmacy Delays

Several complaints cite multi-week delays in prescription fulfillment. This is operationally problematic for migraine sufferers who need acute medication on hand and for women relying on oral contraceptives for pregnancy prevention.

How Thirty Madison Compares to Telehealth Accreditation Standards

The National Committee for Quality Assurance (NCQA) and URAC both offer telehealth organization accreditation programs. Neither Thirty Madison nor its sub-brands currently list NCQA or URAC telehealth accreditation on their websites. These are voluntary programs, and many legitimate telehealth companies have not pursued them. Their absence is not disqualifying, but their presence would meaningfully increase confidence in Thirty Madison's clinical oversight processes.

The Joint Commission's Telehealth Accreditation Program is a third option. Again, not present for Thirty Madison brands as of this review's date.

Telehealth prescribing standards have been addressed by multiple professional bodies. The American College of Obstetricians and Gynecologists (ACOG) published a 2021 committee opinion on telehealth that specifies requirements for medication prescription via remote encounter, including documentation standards and appropriate follow-up intervals [19]. Cove's migraine protocols should meet the American Headache Society's standards of care for remote migraine management. Whether they do cannot be confirmed without reviewing the actual clinical protocols, which Thirty Madison has not made public.

What Patients With Specific Medical Histories Should Know

Certain patient populations face higher risk when using any asynchronous telehealth service, and Thirty Madison's screening processes deserve particular scrutiny for these groups.

Finasteride and Mood Disorders

The FDA updated finasteride's labeling in 2011 and again in subsequent years to include warnings about depression, anxiety, and suicidal ideation [1]. Patients with a personal or family history of depression should have a synchronous clinical encounter before starting finasteride, not only an asynchronous questionnaire. The Post-Finasteride Syndrome Foundation has collected case reports (not controlled-trial data) suggesting persistent sexual and neurological side effects in a subset of users; the FDA is aware of these reports [8].

Oral Contraceptives and Thromboembolism Risk

The CDC's Medical Eligibility Criteria (2024 update) classifies combined oral contraceptives as Category 4 (unacceptable health risk) for women with a history of deep vein thrombosis or pulmonary embolism, known thrombogenic mutations, or current or history of ischemic heart disease [16]. Sadie's intake questionnaire must screen for these conditions. An asynchronous model can miss nuanced histories, particularly when patients do not know their own genetic thrombophilia status.

Tretinoin and Pregnancy

Tretinoin is FDA Pregnancy Category X (teratogenic). Facet's prescribing protocol must include a negative pregnancy test or confirmed non-pregnant status and reliable contraception discussion before initiating therapy [6]. Whether Facet's asynchronous intake is sufficient for this informed-consent requirement is a legitimate clinical question.